Seventy seven of the patients having pulmonary resections had small cell carcinoma (8.4%), and there were six survivors among the 71 with T1-2, N0-1, M0 tumours. The five and 10 year survival rates were both 12%. The histological specimens from these six patients with a small cell ...
Extensive research and clinical trials have identified different chemotherapy medications in the last three decades for the treatment of lung cancer. Response rates with these medications are more than 80% in patients with small-cell lung cancer who were previously untreated. While doctors use some me...
BACKGROUND: Small cell lung cancer (SCLC) is an extremely aggressive tumor with a poor clinical course. Although many efforts have been made to improve patients' survival rates, patients who survive longer than 2 years after chemotherapy are still very rare. We examined the baseline characteristics...
Differences between Advanced Large Cell Neuroendocrine Carcinoma and Advanced Small Cell Lung Cancer: A Propensity Score Matching Analysis Background: Nowadays, the characteristics and treatment of advanced pulmonary large cell neuroendocrine carcinoma (LCNEC) remain controversial. This study ... W Yang,W...
- 1994 - 178 - www.sciencedirect.comdoi:10.1016/0169-5002(94)94461-XELSEVIERLung Cancer
Cell 150, 1121–1134 (2012). Article CAS PubMed PubMed Central Google Scholar Lam, V. K. et al. Targeted tissue and cell-free tumor DNA sequencing of advanced lung squamous-cell carcinoma reveals clinically significant prevalence of actionable alterations. Clin. Lung Cancer 20, 30–36.e33 ...
Small cell neuroendocrine carcinoma of the cervix (SCNECC) is a highly invasive cervical cancer. The immunohistochemical criteria is an important aspect for assistant diagnosis of SCNECC. However, which markers can be appropriate selection for diagnosing SCNECC were not determined. The aim was to sy...
with SCLC [34,35,36]. Some studies identify the involvement of POSTN in the several steps of the metastatic cascade. POSTN participates in tumor-proximal intravasation processes by elevating epithelial-mesenchymal transition (EMT) and motility of clear cell renal cell carcinoma [37]. Meanwhile, ...
inib, not only bind to a hydrophobic pocket beside the ATP binding site of MET but also can block different kinases such as RON, AXL, VEGFR2, etc. Although Cabozantinib was approved for the treatment of advanced medullary thyroid carcinoma and advanced clear-cell renal-cell carcinoma, the ...
SCLC is further divided into two categories: oats-cell cancer [bronchial epithelial cells develop a hostile malignancy neuroendocrine (NE) tumor] and cSCLC (combined small-cell lung cancer and nonsmall cell lung cancer). 2.1.1 Oats-Cell Carcinoma When viewed under a microscope, these canc...